mob

Search This Blog

468x60

728

728x90

468,

250

250+300onk

Background: Hospital-acquired venous thromboembolisms (HA-VTE) are a significant source of morbidity and mortality in spine

 


Abstract

Background: Hospital-acquired venous thromboembolisms (HA-VTE) are a significant source of morbidity and mortality in spine surgery patients. The purpose of this study was to review HA-VTE rates at our institution and evaluate the prevalence of known risk factors in patients who developed HA-VTE among both neurosurgical and orthopedic spine surgeries.

Methods: Retrospective chart reviews were conducted of all spine surgery patients from January 1, 2013, to July 31, 2017, to evaluate rates of HA-VTE and prevalence of known HA-VTE risk factors among these patients. Univariate and multivariate logistic regression analysis for categorical variables and independent Student t test for continuous variables were utilized with significance set at P

Results: The overall HA-VTE rate was 0.94% (0.61% orthopedic, 1.87% neurosurgery). Patients with VTEs had higher rates of thoracic procedure (P = .002), posterior approach (P = .001), diagnosis of fracture (P = .013) or flatback syndrome (P = .028), neurosurgery division (P < .001),< .001),< .001).60 (80% vs 50%, P < .001),

Conclusions: The overall HA-VTE rate at our institution was 0.94% (0.61% orthopedic, 1.87% neurosurgery). In patients who sustained VTE, neurosurgical patients had higher rates of active cancer and age >60 years, and orthopedic patients had higher EBL and rates of anterior-posterior surgery. This highlights the different patient populations between the 2 departments and the need for individualized thromboprophylaxis regimens.

Level of Evidence: 4.

PMID: 32128307 [PubMed]

13:47

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:47

In reply to this message

pubmed: caandvteortroorpul

[Risk factors for hospital mortality during pulmonary embolism].


Related Articles

[Risk factors for hospital mortality during pulmonary embolism].


Ann Cardiol Angeiol (Paris). 2020 Feb 29;:


Authors: El Ghoul J, Bendayekh A, Fki W, Yengui I, Ferjani S, Milouchi S, Ayadi H


No comments:

Post a Comment

اكتب تعليق حول الموضوع

ACERUMEN، زجاجة جرعة واحدة

  جديد   عرض تقديمي 10 زجاجات الموزع أو الشركة المصنعة زينيث فارما تعبير عوامل التوتر السطحي الخفيفة (أسيل ساركوزينات الصوديوم وإستر السكروز...

Search This Blog